The article describing the approval process can by found on Delaware online by Jeff Mordock.
AZ recently brought a lung cancer drug through FDA approval in approximately 2 years. The drug, like ARC ATT, had obtained orphan status and all of the FDA quick approval designations. One factor addressed in the article, was the lack of other treatments. If ATT shows the kind of efficacy we all hope for in early 2016, might it not be a candidate for the same? The AZ drug did not have to go through PIII.
Case, if you want to see something really interesting look to the mid-April FTD. Naked shorting was used to destroy a rally.
Long and strong, as always.
Thanks, HP. Your email confirms my belief that ARWR is a remarkable company. I also believe this company's science is so extraordinary that the rewards down the road to shareholders will also be extraordinary. HP, sharing your conversations with the company is noble on your part, and confirms everything I have thought about the company.
Ex parte communications are generally frowned on by judges when they have a case under review.
Several articles are suggesting a rebound of the biotech sector. So, naturally what happens? The fudsters return and SA hit pieces (adxs) come out. It could not be more obvious that shorty is concerned.
Terry, sorry to take so long getting back to you. I don't know a lot about NVAX, but I understand they have been having some good results with RSV vaccine. In the last few days they have shown the drug is not harmful to infants or pregnant mothers. This was followed with a major grant.
An acquiring company would have to make an offer that placates its shareholders. It is extremely rare for an acquiring company to pay more than 4 times book value and it is usually much less. Do you think ARWR would accept this kind of offer? I don't. I think it is far more likely that a partnership involving the licensing of certain products in ARWR's pipeline would result. As a template, Medimmune recently made a licensing deal with INO for two of its lead products which involved an upfront payment of 27.5 million and a licensing agreement that could approach 700 million on several lead vaccine products.
Geezerbela before jumping to conclusions you should check out the PPS of our competitors like adxs, nvax, awrw all of whom had similar pullbacks this past week.
The only similarity of ARWR to DNDN is that both are biotech stocks and have been attacked by criminal short manipulators. ARWR will overcome the manipulators because of the quality of its science.
This statement from a key analyst combined with heavy volume suggests the beginning of an attempt to manipulate the stock leading into AD. Should they fail in their attempt, it could get very expensive for them.